BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1359 related articles for article (PubMed ID: 8124252)

  • 1. Allogeneic bone marrow transplantation for leukemia with marrow grafts treated by counterflow centrifugation.
    De Witte T; Schattenberg A; Preijers F; Raymakers R; Muus P; Wessels J
    Bone Marrow Transplant; 1993; 12 Suppl 3():S2-6. PubMed ID: 8124252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic bone marrow transplantation for leukemia with marrow grafts depleted of lymphocytes by counterflow centrifugation.
    Schattenberg A; De Witte T; Preijers F; Raemaekers J; Muus P; Van der Lely N; Boezeman J; Wessels J; Van Dijk B; Hoogenhout J
    Blood; 1990 Mar; 75(6):1356-63. PubMed ID: 2310832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome of T cell-depleted transplantation after conditioning with an intensified regimen in patients aged 50 years or more is comparable with that in younger patients.
    Schattenberg A; Schaap N; Preijers F; van der Maazen R; de Witte T
    Bone Marrow Transplant; 2000 Jul; 26(1):17-22. PubMed ID: 10918401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time--a report of the acute leukemia working party of the European group for blood and marrow transplantation (EBMT).
    Frassoni F; Labopin M; Gluckman E; Prentice HG; Vernant JP; Zwaan F; Granena A; Gahrton G; De Witte T; Gratwohl A; Reiffers J; Gorin NC
    Bone Marrow Transplant; 1996 Jan; 17(1):13-8. PubMed ID: 8673048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival in first or second remission after lymphocyte-depleted transplantation for Philadelphia chromosome-positive CML in first chronic phase.
    Schattenberg A; Preijers F; Mensink E; Bär B; Schaap N; Geurts van Kessel A; van der Maazen R; de Witte T
    Bone Marrow Transplant; 1997 Jun; 19(12):1205-12. PubMed ID: 9208114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors in bone marrow transplant recipients with leukaemia. Increased relapse risk in patients treated with ciprofloxacin for gut decontamination.
    Carlens S; Ringdén O; Aschan J; Hägglund H; Ljungman P; Mattsson J; Remberger M
    Clin Transplant; 1998 Apr; 12(2):84-92. PubMed ID: 9575394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of graft-versus-host disease by lymphocyte depletion of the bone marrow graft with use of counterflow centrifugation.
    Haanen C; De Witte T; Plas A; Schattemberg T
    Haematologica; 1991 Mar; 76 Suppl 1():22-8. PubMed ID: 1864551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of the conditioning regimen on erythrocyte chimerism, graft-versus-host disease and relapse after allogeneic transplantation with lymphocyte depleted marrow.
    Bär BM; Schattenberg A; De Man AJ; Hoogenhout MJ; Boezeman J; de Witte T
    Bone Marrow Transplant; 1992 Jul; 10(1):45-52. PubMed ID: 1515878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic matched T-cell-depleted bone marrow transplantation for acute leukemia patients.
    Aristei C; Aversa F; Raymondi C; Marsella AR; Panizza BM; Perrucci E; Piro F; Maranzano E; Lupattelli M; Martelli MF; Latini P
    Cancer J Sci Am; 1996; 2(6):330-4. PubMed ID: 9166553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Graft-versus-leukemia in bone marrow transplantation. The Advisory Committee of the International Bone Marrow Transplant Registry.
    Gale RP; Horowitz MM
    Bone Marrow Transplant; 1990 Jul; 6 Suppl 1():94-7. PubMed ID: 2390646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect.
    Barrett AJ; Mavroudis D; Tisdale J; Molldrem J; Clave E; Dunbar C; Cottler-Fox M; Phang S; Carter C; Okunnieff P; Young NS; Read EJ
    Bone Marrow Transplant; 1998 Mar; 21(6):543-51. PubMed ID: 9543057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.
    Lee CK; deMagalhaes-Silverman M; Hohl RJ; Hayashi M; Buatti J; Wen BC; Schlueter A; Strauss RG; Gingrich RD
    Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term follow-up of patients undergoing allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission after cyclophosphamide-total body irradiation and cyclosporine.
    Mehta J; Powles R; Treleaven J; Horton C; Tait D; Meller S; Pinkerton CR; Middleton G; Eisen T; Singhal S
    Bone Marrow Transplant; 1996 Oct; 18(4):741-6. PubMed ID: 8899189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
    Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.
    Slavin S; Naparstek E; Nagler A; Ackerstein A; Kapelushnik J; Or R
    Exp Hematol; 1995 Dec; 23(14):1553-62. PubMed ID: 8542946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation.
    Huang XJ; Liu DH; Liu KY; Xu LP; Chen H; Han W; Chen YH; Zhang XH; Lu DP
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):257-65. PubMed ID: 19167686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Total body irradiation and high-dose cyclophosphamide, BCNU and VP-16 (CBV) as a new preparatory regimen for allogeneic bone marrow transplantation in patients with advanced hematologic malignancies.
    Wu DP; Milpied N; Moreau P; Mechinaud-Lacroix F; Mahe B; Le Tortorec S; Rapp MJ; Bourdin S; Mahe JM; Harousseau JL
    Bone Marrow Transplant; 1994 Nov; 14(5):751-7. PubMed ID: 7889008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
    Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
    Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of adults with acute myelogenous leukemia in remission given 550 cGy of single-exposure total body irradiation, cyclophosphamide, and unrelated donor bone marrow transplants.
    Hallemeier C; Girgis M; Blum W; Brown R; Khoury H; Goodnough LT; Vij R; Devine S; Wehde M; Postma S; Lin HS; Dipersio J; Adkins D
    Biol Blood Marrow Transplant; 2004 May; 10(5):310-9. PubMed ID: 15111930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 68.